1248 Management LLC Purchases Shares of 348 Thermo Fisher Scientific Inc. $TMO

1248 Management LLC purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the first quarter, HoldingsChannel.com reports. The fund purchased 348 shares of the medical research company’s stock, valued at approximately $173,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Osterweis Capital Management Inc. lifted its stake in Thermo Fisher Scientific by 20.5% in the first quarter. Osterweis Capital Management Inc. now owns 77,455 shares of the medical research company’s stock valued at $38,542,000 after buying an additional 13,169 shares in the last quarter. CBIZ Investment Advisory Services LLC boosted its holdings in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after purchasing an additional 33 shares during the last quarter. Modern Wealth Management LLC grew its position in Thermo Fisher Scientific by 7.4% in the first quarter. Modern Wealth Management LLC now owns 6,074 shares of the medical research company’s stock valued at $3,023,000 after purchasing an additional 420 shares in the last quarter. Jones Financial Companies Lllp grew its position in Thermo Fisher Scientific by 19.6% in the first quarter. Jones Financial Companies Lllp now owns 103,983 shares of the medical research company’s stock valued at $51,920,000 after purchasing an additional 17,068 shares in the last quarter. Finally, Anderson Financial Strategies LLC bought a new position in Thermo Fisher Scientific in the first quarter valued at $30,000. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 over the last ninety days. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $491.29 on Friday. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $623.77. The firm has a market capitalization of $185.52 billion, a P/E ratio of 28.41, a price-to-earnings-growth ratio of 2.54 and a beta of 0.75. The firm’s fifty day moving average price is $465.84 and its two-hundred day moving average price is $452.06. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the previous year, the company earned $5.37 earnings per share. The company’s quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is currently 9.95%.

Analyst Ratings Changes

TMO has been the subject of a number of analyst reports. Evercore ISI decreased their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research report on Tuesday, July 8th. William Blair initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an “outperform” rating for the company. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, September 7th. HSBC reaffirmed a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Scotiabank raised shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target on the stock in a research report on Friday, July 11th. Seventeen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $592.24.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.